Dave Asprey Says Biden's FDA Banned Cheap Peptides to Protect Ozempic — Here's What That Means for You

Dave Asprey Says Biden's FDA Banned Cheap Peptides to Protect Ozempic — Here's What You Should Actually Do Right Now

You were paying $150 a month for compounded semaglutide from a licensed pharmacy. It was working. Then the FDA said the shortage was over, compounders had to stop, and suddenly your only legal option costs $1,000+ per month.

That timeline — and the politics behind it — is exactly what Dave Asprey went public about in early 2025. His claim: the Biden-era FDA didn't ban compounded peptides because of safety concerns. They did it to protect Novo Nordisk and Eli Lilly's revenue. And he believes the MAHA (Make America Healthy Again) movement under the new administration will reverse it.

Is he right? Does it matter? And what should you actually do if you're one of the millions of people caught in the middle?

Important: I'm not a doctor. Everything I share here is based on publicly available regulatory information and published research. Talk to your physician before making any changes to your health regimen.

---

The Bottom Line

• The FDA ended most compounded semaglutide and tirzepatide production in early 2025, citing that the "shortage" was resolved — cutting off affordable access for millions of patients.
• Dave Asprey and other MAHA-aligned voices argue this decision protected Big Pharma profits, not public safety. That claim has merit worth examining, even if the full picture is more complicated.
• MAHA has signaled interest in expanding access to compounded and research peptides, but no concrete policy changes have happened yet as of this writing (May 2026).
• If you were on compounded GLP-1s, you have real options right now — but you need to act proactively, not wait.
• Actionable takeaway: Call your prescriber this week and ask specifically about FDA-approved alternatives, telehealth programs with manufacturer savings cards, and whether any compounding exemptions apply to your situation.

---

What Dave Asprey Actually Said — And Why It Went Viral

In a widely shared interview and follow-up social posts from early 2025, Asprey — the Bulletproof Coffee founder and biohacker — made a pointed accusation: the Biden administration's FDA used the "shortage resolved" designation strategically to shut down compounding pharmacies that were offering semaglutide and other peptides at a fraction of the brand-name price.

His argument, in plain terms: Ozempic costs $900–$1,300 per month at retail. Compounded semaglutide — the same active molecule, made by licensed 503B compounding pharmacies — was running $100–$250 per month. The moment FDA declared the shortage over, that cheap version became illegal to produce at scale. Coincidence?

Asprey doesn't think so. And he's not alone.

The MAHA movement — broadly associated with RFK Jr.'s health policy influence within the new administration — has framed compounding access as a consumer rights and health equity issue. The argument is that wealthy patients will always find access (through cash-pay concierge medicine, international pharmacies, or direct peptide vendors), while middle-class patients lose the affordable option entirely.

Whether you agree with Asprey politically or not, the underlying consumer question is real: did the FDA's timing primarily serve patients, or pharmaceutical patent holders?

---

What Actually Happened With the FDA Compounding Ban

Let's get the facts straight, because this story has been misrepresented in both directions.

The Shortage Designation — and How It Works

The FDA has authority to allow compounding pharmacies to produce copies of commercially available drugs when those drugs are on the official shortage list. During the peak of the GLP-1 craze (2022–2024), Ozempic, Wegovy, Mounjaro, and Zepbound were genuinely, verifiably short. Pharmacies couldn't keep them in stock. Patients waited months.

That shortage created a legal window. Licensed 503A and 503B compounding pharmacies stepped in and produced semaglutide and tirzepatide at scale. Millions of patients got access. Prices dropped dramatically.

Then, in late 2024 and into 2025, the FDA began removing these drugs from the shortage list — first tirzepatide (November 2024), then semaglutide (February 2025). Once a drug comes off the shortage list, large-scale compounding becomes illegal under federal law.

The FDA's stated rationale: supply has caught up with demand. The official shortage is over.

Why Critics — Including Asprey — Pushed Back Hard

The pushback came from multiple directions, and some of it was well-documented.

Several compounding pharmacy associations and patient advocacy groups argued in formal FDA comments that the shortage wasn't actually resolved for all patients — specifically lower-income patients who couldn't afford brand-name pricing even with insurance, and patients in rural areas without easy pharmacy access.

There were also documented cases of manufacturers restricting supply to telehealth channels and smaller pharmacies while prioritizing high-volume retail contracts — behavior that looks a lot like managing scarcity for pricing purposes rather than ramping production to meet demand.

Asprey's framing takes this critique further: he argues the FDA's timeline was politically coordinated with pharmaceutical lobbying. That specific claim is difficult to prove. What's not difficult to prove is that the financial stakes were enormous. Novo Nordisk's semaglutide revenue topped $6 billion in a single quarter in 2024. Compounded semaglutide was a direct threat to that number.

---

What Is MAHA Saying — and Has Anything Actually Changed?

The MAHA movement has made noise about expanding peptide access and reducing pharmaceutical monopoly power. RFK Jr., in his role influencing HHS policy, spoke broadly about Americans' right to access health interventions that work — including compounded medications and research peptides.

As of May 2026, here is what has and hasn't happened:

What has changed:

• There is more regulatory scrutiny of FDA-pharma relationships than there was two years ago.
• Some MAHA-aligned lawmakers have introduced draft legislation to expand compounding rights, though none has passed as of this writing.
• The political climate has shifted enough that several large compounding pharmacies are actively lobbying for re-designation of GLP-1s as shortage drugs.

What has not changed:

• The FDA's shortage designations for semaglutide and tirzepatide remain in place. Large-scale compounding is still prohibited.
• No executive order has reversed the compounding ban.
• Research peptides like BPC-157, CJC-1295, and ipamorelin remain in a gray zone — not FDA-approved for human use, not banned outright, but subject to FDA enforcement discretion.

The honest takeaway: MAHA has changed the conversation. It has not yet changed the rules.

---

Who Is Actually Affected — And How Badly?

This isn't an abstract policy debate. Real people are making real decisions right now.

If You Were on Compounded Semaglutide or Tirzepatide

You lost access to the affordable version. Your options are now:

1. Brand-name medication with a savings card. Novo Nordisk and Eli Lilly both offer patient assistance programs. If your household income qualifies, you may be able to get Ozempic or Wegovy for $25–$50/month. Ask your doctor about this specifically — many patients don't know it exists.

2. Telehealth programs with direct pricing. Some telehealth platforms have negotiated rates with manufacturers or operate their own licensed dispensing. Pricing varies widely. Do your research before committing.

3. Insurance coverage. GLP-1s for obesity are still not covered by most plans, but coverage for type 2 diabetes is more common. If you have a metabolic health diagnosis, your coverage landscape may be different than you think.

4. 503A compounding with a patient-specific prescription. Individual patient compounding (503A) is still technically legal in some circumstances — it just can't be done at scale. Some physicians can still prescribe compounded semaglutide for specific documented clinical needs. This is a narrowing window, not a guaranteed option.

5. Clinical trials. If you haven't tried GLP-1s yet or are looking for next-generation options, trials for newer compounds like retatrutide are still enrolling. You can search ClinicalTrials.gov for options near you.

If You Were Using Research Peptides (BPC-157, Ipamorelin, etc.)

Note: These compounds are not FDA-approved for human use. The information below is based on preclinical research and publicly available regulatory information. This is not a recommendation to use these compounds. Consult a qualified healthcare provider.

The regulatory status of research peptides hasn't dramatically changed under MAHA — yet. But the enforcement climate has shifted slightly. The FDA has historically pursued compounding pharmacies and vendors selling research peptides for human use. That enforcement hasn't disappeared, but the current administration has been less aggressive in some areas.

If you were sourcing research peptides through a licensed physician or compounding pharmacy, verify their current legal status with your provider. The landscape changes faster than any blog post can keep up with.

---

The Bigger Question Asprey Is Really Asking

Strip away the politics and Asprey is raising a consumer rights question that deserves a direct answer: Should pharmaceutical patent protection prevent patients from accessing more affordable versions of medications that demonstrably help them?

This isn't a new debate. It's the same argument that drove the push for generic drugs in the 1980s. It's the same argument behind Medicare drug price negotiation. The specific wrinkle with compounded GLP-1s is that the branded drugs are still under patent — so compounders were operating in a legal gray zone that only existed because of the shortage designation.

When the shortage ended (or was declared ended), that gray zone closed.

Whether that was the right call depends on who you think the FDA's primary obligation is to: manufacturers who fund FDA operations through user fees, or patients who need access to affordable medicine. That tension is real, documented, and worth your attention regardless of your politics.

---

What the Research Says About the Medications at the Center of This Fight

It's worth remembering why this matters medically, not just politically.

Semaglutide and tirzepatide have strong research backing for weight management and metabolic health. Across multiple large-scale trials, tirzepatide produced average weight loss of 15–22% of body weight — a result that, before these drugs existed, would have required bariatric surgery to achieve consistently. Semaglutide showed similar results in the STEP trials, with participants losing an average of 15% of body weight over 68 weeks, according to research published in the New England Journal of Medicine.

These aren't marginal benefits. For patients with obesity-related conditions — metabolic syndrome, sleep apnea, joint disease, cardiovascular risk — this is meaningful, life-changing medicine.

That's what makes the access question urgent. When a medication this effective is priced out of reach for most patients, and the affordable alternative gets banned, people don't just switch to the expensive version. Most of them go without. And going without has real health consequences.

---

What to Watch For Next — Your Early Warning System

The policy situation is moving. Here's what to monitor:

Watch the FDA shortage list. If semaglutide or tirzepatide is re-added to the shortage list — which some pharmacy advocacy groups are actively pushing for — compounding access could reopen legally. Check FDA Drug Shortages directly.

Watch for compounding legislation. Several bills expanding compounding rights have been introduced in Congress. None have passed. If one gains traction, it will make news. Follow it.

Watch MAHA's concrete policy moves. Asprey and others in the MAHA orbit have made a lot of promises. The question is whether those promises translate into regulatory action. Speeches don't change the shortage list. Executive action or legislation does.

Watch your prescriber. This situation is evolving week by week. Your doctor or telehealth provider should be your first call — not a blog post — for the most current options.

---

FAQ: What People Are Actually Searching Right Now

Is compounded semaglutide still legal in 2025/2026? Large-scale compounding of semaglutide is no longer permitted since the FDA removed it from the shortage list in early 2025. Some individual patient (503A) compounding may still be legal depending on your state and specific clinical circumstances. Ask your physician.

Did the FDA ban peptides to protect Ozempic? The FDA's official position is that it ended compounding authorization because the shortage was resolved. Critics, including Dave Asprey, argue the timing and enforcement benefited pharmaceutical manufacturers. The full truth likely contains elements of both — regulatory decisions are rarely made in a vacuum, and the financial stakes were enormous.

What is MAHA's position on peptides and compounding? MAHA has expressed support for expanding consumer access to compounded medications and research peptides. As of May 2026, this has not resulted in concrete policy changes that restore compounded GLP-1 access.

What are my options if I can't afford brand-name Ozempic or Wegovy? Manufacturer savings programs, telehealth platforms with negotiated pricing, insurance coverage (especially for diabetes indications), and clinical trial enrollment are all viable paths. Call your prescriber this week and ask specifically about each of these.

Are research peptides like BPC-157 affected by this? Research peptides operate in a separate regulatory category — they are not FDA-approved for human use and have different legal considerations than compounded versions of FDA-approved drugs. Their status hasn't dramatically changed, but enforcement is unpredictable. Consult a healthcare provider familiar with this space.

---

Conclusion: The Action Plan You Can Use Today

Here's the honest summary: Dave Asprey is raising a real consumer issue wrapped in political framing. The access problem is genuine. The policy fix hasn't arrived yet. And in the meantime, real patients are making harder choices.

If you're affected, here's your action plan for this week:

1. Call your prescriber today. Ask about manufacturer assistance programs, 503A compounding options in your state, and current telehealth alternatives.
2. Check the FDA shortage list yourself. It changes. Your situation could change with it.
3. Look into clinical trials at ClinicalTrials.gov if you haven't yet started a GLP-1 or are interested in next-generation options.
4. Follow the MAHA policy news — not the hype, the actual regulatory filings and legislation. That's where real change will show up first.
5. Don't buy from unregulated sources. The desperation is understandable. The risks are real. If you can't afford the brand-name drug and can't access compounded versions legally, work with a physician to find a path — not around the system.

This situation will keep evolving. We'll keep covering it as it does.

---

Medical Disclaimer: The information on this website is for educational and informational purposes only. It is not intended as medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before starting any peptide protocol, medication, or supplement regimen. Individual results vary. The author shares personal experience and published research — not medical recommendations.

---

Sources

1. Semaglutide weight loss trial — STEP 1 results — New England Journal of Medicine, 2021
2. FDA Drug Shortage Database — U.S. Food and Drug Administration
3. Tirzepatide SURMOUNT-1 trial results — New England Journal of Medicine, 2022
4. FDA compounding guidance for 503A and 503B pharmacies — FDA.gov
5. ClinicalTrials.gov — GLP-1 receptor agonist trials currently enrolling — U.S. National Library of Medicine
6. [Glucagon-